Assessment of peripheral blood CD4+adenosine triphosphate activity in patients with rheumatoid arthritis
Assessment of peripheral blood CD4+adenosine triphosphate activity in patients with rheumatoid arthritis
复制标题
DOI：
10.1007/s10165-012-0621-1
复制
发表时间：
2013-01-01
影响因子：
2.2
通讯作者：
Arima, Naomichi
中科院分区：
文献类型：
--
作者：
Akimoto, Masaki;Yunoue, Shingo;Arima, Naomichi
检测了ImmuKnow（Cylex）测定法预测接受合成或生物疾病缓解抗风湿药物（DMARD）的类风湿性关节炎（RA）患者感染风险的能力。在来自117名未感染RA患者和17名感染RA患者的全血中测量了响应于植物血凝素的由CD 4+细胞产生的三磷酸腺苷（ATP）的量，与75例健康对照组比较，感染组ATP水平显著低于健康对照组（P < 0.0005）和非感染组（P = 0.040）。无感染组的平均ATP水平显著低于健康对照组（P = 0.012）。在28个关节中，ATP水平与疾病活动性评分之间没有相关性。ImmuKnow检测结果可能有效地识别RA患者感染风险增加，但结果显示与RA活动性无关。需要更大规模的研究来确定该检测在RA治疗中的临床优势。
The ability of the ImmuKnow (Cylex) assay to predict the risk of infection in rheumatoid arthritis (RA) patients receiving synthetic or biological disease-modifying antirheumatic drugs (DMARDs) was examined.The amount of adenosine triphosphate (ATP) produced by CD4+ cells in response to phytohemagglutinin was measured in whole blood from 117 RA patients without infection versus 17 RA patients with infection, and compared with results in 75 healthy controls.The mean ATP level was significantly lower in patients with infection compared to both healthy controls (P < 0.0005) and patients without infection (P = 0.040). Also, the mean ATP level in patients without infection was significantly lower than that in healthy controls (P = 0.012). There was no correlation between the ATP level and the Disease Activity Score in 28 joints.ImmuKnow assay results may be effective in identifying RA patients at increased risk of infection, but the results showed no correlation with RA activity. Larger studies are required to establish the clinical advantages of this assay in RA treatment.